Clinical trial / 2016
Inulin-propionate ester (IPE-27) significantly reduced ad libitum energy intake compared with inulin control and IPE-54 in a crossover trial.
Researchers developed inulin short-chain fatty acid esters to deliver propionate directly to the colon and tested them in vitro and in humans. In a randomized controlled crossover study, participants received 10 g/day of IPE-27, IPE-54, or inulin control for 7 days. In vivo, IPE-27 produced greater 13C recovery in breath CO2 than IPE-54 (64.9 vs. 24.9%, P = 0.001) and reduced energy intake during an ad libitum test meal compared with inulin (439.5 vs. 703.9 kcal, P = 0.025) and IPE-54 (439.5 vs. 659.3 kcal, P = 0.025). Intake with IPE-54 did not differ significantly from inulin control.
- Study type
- Randomized controlled crossover study and in vitro fermentations
- Who was studied
- Human participants (sample size not specified)
- What was measured
- Ad libitum food intake (kcal) and 13C recovery in breath CO2
THE PAPER
Randomised clinical study: inulin short-chain fatty acid esters for targeted delivery of short-chain fatty acids to the human colon.
Polyviou T, MacDougall K, Chambers ES, Viardot A, Psichas A, Jawaid S, Harris HC, Edwards CA, Simpson L, Murphy KG, Zac-Varghese SE, Blundell JE, Dhillo WS, Bloom SR, Frost GS, Preston T, Tedford MC, Morrison DJ. Aliment Pharmacol Ther, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.